INDIANAPOLIS AND MOUNT ROYAL, N.J., June 9, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the American Migraine Foundation announced today that Lilly will provide a $1 million grant to the American Migraine Foundation to sponsor the development of the American Registry for Migraine Research (ARMR), a large-scale, publicly-accessible headache registry and biological repository that will contain clinical, biologic and neuroimaging data to further advance the research and discovery of new treatments for migraine.
Migraine is the third-most prevalent and sixth-most disabling medical disorder in the world, and it is the leading cause of all disability attributed to neurological diseases worldwide.1,2 Other primary and secondary headache disorders are also highly prevalent and cause substantial burden for people with these diseases, including impaired quality of life and financial cost.1
Through this registry, the American Migraine Foundation aims to establish repositories and enroll patients with primary and secondary headache disorders to collect imaging data, genetics information and biologic samples. The American Migraine Foundation will also work to establish and train a larger network of investigative sites to enroll subjects, submit data and access all collected data for specific studies. Data from the registry will be made accessible to all researchers, with grant applications available for high-priority projects.
"We are enormously grateful for the vision and very generous support from Lilly to help the American Migraine Foundation build and sustain a patient registry and biorepository for migraine and other headache disorders," said American Migraine Foundation Chairman Dr. David Dodick. "We believe the knowledge gained from this registry and the potential to identify clinical, laboratory, imaging and genetic biomarkers will usher in an era of precision medicine and generate new targets for generations of patients to come."
As a platinum sponsor, Lilly will serve as a member of the Corporate Registry Roundtable, working with the American Migraine Foundation and other members to propose topics and analysis areas for the registry, which will be approved by the ARMR Scientific Review Board.
"Despite the prevalence and overwhelming impact they cause, migraine and other headache disorders historically are some of the most underfunded areas of clinical research," said Dr. Robert Conley, Distinguished Lilly Scholar and leader of Lilly's pain development platform. "We are proud to support the American Migraine Foundation's efforts to establish a registry that will allow researchers to evaluate and compare real-world data that can help transform research in headache disorders, and ultimately help healthcare providers improve outcomes for people living with these devastating disorders."
About Migraine
Migraine is a neurological disease characterized by recurrent episodes of severe headache, often accompanied by a variety of other symptoms, including nausea, vomiting, sensitivity to light and sound and changes in vision.2,3 Thirty-six million Americans, about 12 percent of the population, suffer from migraines at least periodically.3 Migraine can be extremely disabling and costly, accounting for more than $20 billion in direct (e.g. doctor visits, medications) and indirect (e.g. missed work, lost productivity) expenses each year in the United States.3 There currently is no cure for migraine.3
About the American Migraine Foundation
The American Migraine Foundation is a non-profit foundation supported by the American Headache Society and generous donors dedicated to the advancement of migraine research. Its mission is to support innovative research that will lead to improvement in the lives of those who suffer from migraine and other disabling headaches. www.americanmigrainefoundation.org is the companion website to the American Headache Society (www.americanheadachesociety.org), the professional services organization for the world's foremost clinicians and researchers working in migraine.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. P-LLY
1 Steiner TJ, Stovner LJ, Birbeck GL. Migraine: the seventh disabler. The Journal of Headache and Pain. 2013;14(1):1.
2 Headache disorders. World Health Organization website. http://www.who.int/mediacentre/factsheets/fs277/en/. Accessed June 8, 2016.
3 Types of Headache/Migraine. American Migraine Foundation website. https://americanmigrainefoundation.org/living-with-migraines/types-of-headachemigraine/ Accessed June 8, 2016.
Refer to: Scott MacGregor; jsmacgregor@lilly.com; 317-440-4699 (Lilly)
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-and-american-migraine-foundation-announce-1-million-grant-for-launch-of-first-patient-registry-to-advance-research-and-development-in-migraine-300282422.html
SOURCE Eli Lilly and Company
